Price$36.91-1.00 (-2.64%)
01:30 PM07:30 PM
News · 26 weeks38+400%
2026-04-192026-10-11
Mix1790d
- SEC Filings11(65%)
- Other5(29%)
- Analyst1(6%)
Latest news
25 items- PRCancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research AgendaSAN DIEGO, Oct. 14, 2026 /CNW/ -- Equity Insider News Commentary - Global spending on cancer medicines reached $252 billion in 2024 and is forecast to exceed $400 billion by 2028, according to the IQVIA Institute, with the United States accounting for roughly 46% of the total. The pace of new treatments has picked up with it: about 150 new active substances entered the U.S. oncology market between 2015 and 2024, and launch activity in 2020 to 2024 ran nearly 40% ahead of the prior five years. Active Companies from around the markets with current developments this week include: Oncolytics Biotech, Inc. (NASDAQ:ONCY), Revolution Medicines, Inc. (NASDAQ:RVMD), Eli Lilly and Company (NYSE:LLY),
- SECSEC Form 6-K filed by Genmab A/S6-K - GENMAB A/S (0001434265) (Filer)
- PRGenmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2026Company Announcement Net sales of DARZALEX® in the third quarter of 2026 totaled USD 4,239 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN, Denmark; October 13, 2026 – Genmab A/S (NASDAQ:GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as reported by J&J were USD 4,239 million in the third quarter of 2026. Net trade sales were USD 2,528 million in the U.S. and USD 1,711 million in the rest of the world. Genmab receives royalties on the
- SECSEC Form 6-K filed by Genmab A/S6-K - GENMAB A/S (0001434265) (Filer)
- SECSEC Form 6-K filed by Genmab A/S6-K - GENMAB A/S (0001434265) (Filer)
- PRGenmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian CancerTreatment with Rina-S® 120 mg/m² every three weeks demonstrated a clinically meaningful objective response rate (ORR) and durable median duration of response (mDOR) in patients with platinum-resistant ovarian cancer (PROC) Antitumor activity was observed regardless of folate receptor alpha (FRα) expression levels, including low FRα expression and non-expressors Genmab A/S (NASDAQ:GMAB) today announced results from Part C of the Phase 1/2 RAINFOL™-01 trial evaluating rinatabart sesutecan (Rina-S), an investigational folate receptor alpha (FRα)-targeted, topoisomerase I (TOPO1)-inhibitor antibody-drug conjugate (ADC), demonstrated that among 109 treated patients with platinum-resistant
- SECSEC Form 6-K filed by Genmab A/S6-K - GENMAB A/S (0001434265) (Filer)
- PRMajor Shareholder AnnouncementCompany Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; October 2, 2026 – Genmab A/S (NASDAQ:GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Darwin Global Management Limited ("Darwin") has informed us that, as of September 28, 2026, Darwin through shares and ADRs held by certain investment funds and portfolios for which Darwin acts as investment manager, controls the voting rights attached to 3,188,361 shares in Genmab A/S, corresponding to 5.11% of the voting rights in Genmab A/S. About Genmab Genmab is an international biotechnology company dedicated to improving the lives of people with cancer and other serious dise
- SECSEC Form 6-K filed by Genmab A/S6-K - GENMAB A/S (0001434265) (Filer)
- SECSEC Form 6-K filed by Genmab A/S6-K - GENMAB A/S (0001434265) (Filer)
- SECSEC Form 6-K filed by Genmab A/S6-K - GENMAB A/S (0001434265) (Filer)
- SECSEC Form 6-K filed by Genmab A/S6-K - GENMAB A/S (0001434265) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Genmab A/SSCHEDULE 13G/A - GENMAB A/S (0001434265) (Subject)
- SECSEC Form 6-K filed by Genmab A/S6-K - GENMAB A/S (0001434265) (Filer)
- SECSEC Form 6-K filed by Genmab A/S6-K - GENMAB A/S (0001434265) (Filer)
- SECSEC Form 6-K filed by Genmab A/S6-K - GENMAB A/S (0001434265) (Filer)
- ANALYSTGenmab upgraded by TD Cowen with a new price targetTD Cowen upgraded Genmab from Hold to Buy and set a new price target of $43.00
- SECSEC Form 6-K filed by Genmab A/S6-K - GENMAB A/S (0001434265) (Filer)
- PRGenmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2026Company Announcement Net sales of DARZALEX® in the second quarter of 2026 totaled USD 4,207 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN, Denmark; July 15, 2026 – Genmab A/S (NASDAQ:GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as reported by J&J were USD 4,207 million in the second quarter of 2026. Net trade sales were USD 2,435 million in the U.S. and USD 1,772 million in the rest of the world. Genmab receives royalties on the w
- PRGenmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular LymphomaTEPKINLY® (epcoritamab) plus lenalidomide and rituximab (R2) is the first and only bispecific-based therapy approved in Europe for the treatment of follicular lymphoma in the second-line setting, offering a chemotherapy-free option In the Phase 3 EPCORE® FL-1 trial, fixed-duration TEPKINLY + R2 demonstrated significantly superior progression-free survival and overall response rates compared to R2, with approximately three out of four patients achieving a complete response Genmab A/S (NASDAQ:GMAB) announced today that the European Commission (EC) granted marketing authorization for TEPKINLY® (epcoritamab) in combination with lenalidomide and rituximab (TEPKINLY + R2) for the treatment
- SECSEC Form 6-K filed by Genmab A/S6-K - GENMAB A/S (0001434265) (Filer)
- SECSEC Form 6-K filed by Genmab A/S6-K - GENMAB A/S (0001434265) (Filer)
- SECSEC Form 6-K filed by Genmab A/S6-K - GENMAB A/S (0001434265) (Filer)
- SECSEC Form 6-K filed by Genmab A/S6-K - GENMAB A/S (0001434265) (Filer)
- PRMajor Shareholder AnnouncementCompany Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; June 15, 2026 – Genmab A/S (NASDAQ:GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Orbis Investment Management Limited has informed us that through shares, as of June 12, 2026, Orbis Investment Management Limited controlled the voting rights to 3,112,476 shares in Genmab A/S, which amounts to 4.99% of the share capital and voting rights in Genmab A/S. The major shareholder announcement of Orbis Investment Management Limited is attached to this announcement. About Genmab Genmab is an international biotechnology company dedicated to improving the lives of people wi
GMAB FAQ
7 questionsWhat does Genmab A/S do?
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumumab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Arzerra for treating CLL. Its products under development include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; tisotumab vedotin for treating cervical, ovarian, and solid cancers...Where does GMAB stock trade?
Genmab A/S (GMAB) is listed on NASDAQ.What sector and industry is GMAB in?
Genmab A/S operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Genmab A/S go public?
Genmab A/S (GMAB) completed its IPO in 2019.What are analysts saying about GMAB?
Genmab A/S has had 8 recent analyst actions on file. The most recent action was from TD Cowen: Buy with a $4300.00 price target on 2026-07-22. Recent price targets range from $3200.00 to $4300.00.What companies are similar to GMAB?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare GMAB side-by-side with any of them on Quantisnow.How can I track GMAB on Quantisnow?
Quantisnow aggregates Genmab A/S's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow GMAB to receive live email and push alerts on every new disclosure.